Cialis
Product Images NDC 54868-4665

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 54868-4665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 10 mg Package Label (4665)

Cialis 10 mg tablet bottle label from Physicians Total Care, Inc. The label includes active ingredient tadalafil, container size of 6 tablets, and directions indicating it contains 6 tablets each with 10 mg strength. It also displays caution about federal law prohibiting dispensing without prescription, storage instructions, manufacturer information, lot number, and expiration date.*

FDA Label Image

Image Of 20 mg Package Label (4968)

Cialis 20 mg tablet bottle label from Physicians Total Care, Inc. The label states contents of 16 tablets, each containing 20 mg of tadalafil. It includes dosage instructions, child safety warnings, storage conditions at room temperature, and a caution that federal law prohibits dispensing without prescription. The label features the Physicians Total Care logo and a barcode.*

FDA Label Image

Image Of 5 mg Package Label (5956)

Packaging label for Cialis 5 mg tablets showing the labeler as Physicians Total Care, Inc. The label includes the lot number, expiration date, and a barcode. Manufacturing is attributed to Eli Lilly and Company, Indianapolis, IN.*

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

Chemical structure diagram of the active ingredient in Cialis. The structure includes a bicyclic ring fused to a piperidine ring and a substituted phenyl group, typical of tadalafil's molecular configuration.*

FDA Label Image

Figure (Cialis Uspi F001 V2)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) comparing single 20-mg and 5-mg tadalafil doses and once-daily 5-mg tadalafil after 5 days. The graph includes error bars indicating variability at each time point, illustrating pharmacokinetic profiles for Cialis.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

A set of four line graphs showing the difference in blood pressure (systolic and diastolic) between Tadalafil and placebo over time in hours, including standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure measurements, with error bars indicating variability.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

Two line graphs plotting systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure changes, comparing Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure changes over the same period and treatment comparison.*

FDA Label Image

Figure (Cialis Uspi F004 V1)

A line graph depicting systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin given at 08:00 and 20:00. Four lines compare the blood pressure effects of tadalafil and placebo at the two dosing times.*

FDA Label Image

Figure 5 (Cialis Uspi F005 V1)

A line graph depicting the change from baseline in IPSS total score over 12 weeks of treatment, comparing Cialis 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change in IPSS total score. Cialis 5 mg group shows a greater decrease over time compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Figure 6 (Cialis Uspi F006 V1)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Cialis 5 mg and a placebo. The x-axis shows the duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows the change in IPSS score. Data points for Cialis 5 mg and placebo are connected by solid and dashed lines respectively, with statistically significant differences marked by asterisks at weeks 4 and 12.*

FDA Label Image

Figure 7 (Cialis Uspi F007 V1)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration, comparing Cialis 5mg and placebo. The vertical axis represents the score change, with more negative values indicating greater improvement. Cialis 5mg shows a greater decrease in IPSS score than placebo, with a statistically significant difference at 12 weeks (p < 0.01). The horizontal axis shows the treatment duration in weeks (0, 2, 4, 8, 12).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.